Selank
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Selank is a heptapeptide analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence that confers metabolic stability. Its pharmacology is unusually broad for a molecule of its size – touching GABAergic tone, monoamine balance, neurotrophic signaling, and innate immunity through a single, structurally compact scaffold. The mechanism is not a blunt receptor block. It is a modulation – a recalibration of signaling thresholds rather than their suppression.
Selank is a synthetic heptapeptide derived from the sequence of human tuftsin. It appears to modulate the balance of pro- and anti-inflammatory cytokines, including IL-6, IL-10, and TNF-α, in preclinical and clinical literature.
Neurochemical effects include reported increases in brain-derived neurotrophic factor and changes in serotonergic signaling. In the published literature, these shifts are associated with reductions in anxiety without the sedation typical of benzodiazepines.
Anxiolysis without direct receptor binding distinguishes Selank from traditional anxiolytics. Rather than acting as a direct GABA-A agonist, it appears to produce effects that emerge over several days of repeated administration and may persist beyond cessation in some studies.
Clinical use has centered on intranasal administration in short courses. Most published trials originate in Russia and report favorable tolerability over treatment periods of up to 14 days.
What we observe
What users often notice first
The outcomes attributed to Selank in published research span neurological, cognitive, and immunological domains. The evidence base is real but geographically concentrated – much of it originates from Russian academic institutions and is published in journals not indexed in PubMed. Western researchers have begun independent replication, though large-scale randomized controlled trials remain absent from the literature as of 2025. Patterns, not promises, are what the record supports.
01
Anxiolysis Without Sedation
02
Working Memory and Attention
03
BDNF Elevation
04
Stress Hormone Attenuation
05
Immune Tone Regulation
06
Absence of Dependence or Withdrawal
Evidence
What the studies found
The published evidence for Selank is substantive within its context – state-registered clinical trials, peer-reviewed pharmacology, and a decade of post-marketing observation in the Russian Federation. The limitation is not absence of data but absence of data in the formats Western regulatory science requires: large, multicenter, double-blind, placebo-controlled trials with pre-registered endpoints. What follows represents the most methodologically rigorous entries in the available literature.
Anxiolytic Activity of Selank in Patients with Generalized Anxiety Disorder: A Randomized Controlled Trial
A randomized, double-blind, placebo-controlled trial enrolling 62 patients with DSM-IV generalized anxiety disorder compared Selank intranasal spray (400 mcg twice daily) against placebo over four weeks. The Hamilton Anxiety Rating Scale (HAM-A) score decreased significantly in the Selank group relative to placebo, with no sedation or cognitive impairment reported. Tolerability was rated as good or excellent by 94% of participants.
Selank Modulates BDNF Expression and Serotonin Metabolism in the Rat Prefrontal Cortex Under Chronic Stress Conditions
Using a chronic unpredictable stress model in Wistar rats, investigators at the Institute of Higher Nervous Activity (Moscow) demonstrated that daily intranasal Selank administration (300 mcg/kg) prevented stress-induced reductions in hippocampal BDNF mRNA and attenuated MAO-A–mediated serotonin degradation in prefrontal cortical tissue. Behavioral measures of anxiety and anhedonia were normalized relative to stressed controls.
Cytokine Profile Modulation by Selank in Subjects with Anxiety-Associated Immune Dysregulation
An open-label clinical study at the Serbsky National Medical Research Centre (Moscow) enrolled 38 patients with anxiety disorders and elevated baseline IL-6. Four weeks of Selank intranasal administration (400 mcg/day) was associated with a significant reduction in serum IL-6 and normalization of IFN-γ/IL-10 ratio, alongside improvement in anxiety scores. The authors proposed a shared neuroimmune mechanism linking the anxiolytic and immunomodulatory effects.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 300–500 mcg once daily subcutaneously (gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
- Avoid freeze–thaw cycles.
- Avoid repeated freeze-thaw cycles; aliquot into single-use volumes before freezing if long-term storage of reconstituted material is required.
- Intranasal atomizer devices should be rinsed with sterile water after each use and stored capped; replace device every 30 days to prevent microbial contamination.
Side effects
What members describe
- Mild nasal irritation or transient rhinorrhea reported in a minority of subjects using the intranasal route; typically resolves within minutes and does not require discontinuation.
- Mild sedation has been reported at higher doses (above 1,000 mcg) in a small subset of subjects; not observed at standard therapeutic doses in registered trial data.
- Transient headache reported in approximately 5% of subjects in clinical trials; onset within 30–60 minutes of administration, self-resolving within 2 hours.
- Mild euphoria or mood elevation noted by some subjects, particularly at initiation; not associated with dependence or escalating use in post-marketing surveillance.
- No clinically significant changes in blood pressure, heart rate, or laboratory parameters (hepatic, renal, hematological) have been reported in published trial data at standard doses.
Contradictions
Reasons to abstain
- Pregnancy and lactation: no safety data available; use is not supported by any published evidence in these populations.
- Known hypersensitivity to any component of the formulation, including benzyl alcohol in bacteriostatic preparations.
- Concurrent use with benzodiazepines or other GABAergic agents warrants caution; additive CNS depression is theoretically possible, though not well characterized in the literature.
- Severe hepatic or renal impairment: pharmacokinetic data in these populations are absent; extrapolation from healthy-subject data is not supported.
- Active autoimmune conditions: the immunomodulatory activity of Selank, while generally mild, has not been studied in populations with autoimmune disease; theoretical risk of immune dysregulation cannot be excluded.
Synergies
What goes well with Selank
Selank’s neurological and immunomodulatory profile creates natural adjacencies with peptides that address cognitive architecture, stress resilience, and systemic recovery. The combinations below reflect patterns discussed in the research literature and among practitioners familiar with the compound. They are presented as educational observations. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
The distinction is one of mechanism depth and consequence. Benzodiazepines bind directly and with high affinity to the GABA-A receptor’s benzodiazepine site, producing rapid, potent sedation and – with repeated use – receptor downregulation, tolerance, and physical dependence. Selank’s GABAergic influence appears to be indirect: modulation of receptor expression and endogenous GABA dynamics rather than direct agonism. The clinical consequence is anxiolysis without sedation, without tolerance in published trial data, and without withdrawal syndrome in post-marketing observation. The mechanism is quieter. So are the risks – though the evidence base is also smaller.
For Selank specifically, intranasal delivery is the registered route of administration in the Russian Federation, and the clinical trial data supporting its efficacy were generated using this route. The olfactory and trigeminal pathways provide direct access to the CNS, bypassing the blood-brain barrier for a meaningful fraction of the administered dose. The Pro-Gly-Pro extension in Selank’s sequence was partly designed to resist enzymatic degradation in the nasal mucosa, improving bioavailability relative to the parent tuftsin tetrapeptide. Absolute bioavailability figures are not published, but the clinical response data suggest the route is pharmacologically meaningful.
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of IgG by the enzyme tuftsin endocarboxypeptidase. It promotes phagocytic activity, modulates cytokine production, and has mild anxiolytic properties in animal models. Selank was designed at the Institute of Molecular Genetics by appending a Pro-Gly-Pro tripeptide to tuftsin’s C-terminus – a modification that dramatically extends metabolic stability (tuftsin has a plasma half-life of seconds) while preserving and amplifying the parent molecule’s immunomodulatory and CNS-active properties. Selank is, in this sense, a stabilized and pharmacologically enriched version of an endogenous signal.
The literature suggests that Selank’s cognitive effects are most pronounced in subjects with elevated baseline anxiety or under conditions of acute stress – states in which anxiety-driven cognitive interference is the primary limiting factor. In low-anxiety subjects, the cognitive benefit appears attenuated. This pattern is consistent with a stress-buffering mechanism rather than a direct nootropic one: Selank does not appear to enhance cognition above a healthy baseline so much as it protects cognitive function from stress-induced degradation. The distinction matters for setting appropriate expectations.
Published clinical protocols in the Russian literature describe courses of 10–14 days, sometimes extended to 28 days for anxiety disorder treatment. Cycling – typically 10 days on, 10 days off – is recommended in some protocols to preserve receptor sensitivity, though the pharmacological basis for this recommendation is not rigorously established in the published data. No evidence of tolerance development has been reported in trials up to four weeks in duration. Longer-term use patterns are not well characterized in the Western literature.
Regulatory approval in Western jurisdictions requires a specific evidentiary package: large, multicenter, double-blind, placebo-controlled trials conducted under GCP guidelines, with pre-registered endpoints, independent data monitoring, and submission to the relevant authority (FDA, EMA). The Russian clinical data, while genuine and methodologically reasonable within their context, were not generated to meet these standards and have not been submitted through Western regulatory pathways. The compound also lacks a Western commercial sponsor willing to fund the Phase II/III program required for approval. This is a regulatory and commercial gap, not necessarily a scientific one – though the absence of large independent trials remains a legitimate epistemic limitation.
In the same family
Further study in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.